Cost-effectiveness of insulin glargine versus NPH insulin in type 1 diabetes using basal bolus treatment in a German setting

Peter K. Sch├Ądlich, Franz-Werner Dippel, Katharina C. Koltermann & Martin Pfohl
Introduction: Basal insulin analogues are well established in the treatment of type 1 diabetes. Yet only little is known about their economic impact. The aim of this study therefore was to compare, from the perspective of the Statutory Health Insurance (SHI), the cost effectiveness of the long-acting[for full text, please go to the a.m. URL]